Despite the routine use of procedural anti-coagulation and anti-platelet therapy for FFR
calculation, no study has evaluated the optimal anti-thrombotic regimen in patients
undergoing FFR. Therefore, the aim of the Evaluation of Simplified Anti-Thrombotic Therapy
for Coronary Fractional Flow Reserve (SMART-FFR) study was to evaluate the safety of using a
simplified anti-thrombotic regimen with only upstream dual anti-platelet therapy (DAT) with
aspirin and clopidogrel, compared with anticoagulation plus single- or- DAT therapy in
patients with intermediate coronary artery stenosis undergoing FFR calculation during
elective coronary angiography.